Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q68CP4: Variant p.Leu473Pro

Heparan-alpha-glucosaminide N-acetyltransferase
Gene: HGSNAT
Feedback?
Variant information Variant position: help 473 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Leucine (L) to Proline (P) at position 473 (L473P, p.Leu473Pro). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In MPS3C; shows practically no enzyme activity. Any additional useful information about the variant.


Sequence information Variant position: help 473 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 663 The length of the canonical sequence.
Location on the sequence: help IGDFGKYPNCTGGAAGYIDR L LLGDDHLYQHPSSAVLYHTE The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         IGDFGKYPNCTGGAAGYIDRLLLGDDHLYQHPSSAVLYHTE

Mouse                         IGDLGKYPHCTGGAAGYIDRLLLGDNHLYQHPSSTVLYHTE
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 663 Heparan-alpha-glucosaminide N-acetyltransferase
Topological domain 442 – 500 Lumenal, vesicle
Mutagenesis 462 – 462 C -> S. Complete loss of intralysosomal proteolytic cleavage and enzymatic activity. Reduced oligomer formation.
Mutagenesis 479 – 479 H -> A. Loss of intralysosomal proteolytic cleavage and enzymatic activity, retained in the endoplasmic reticulum.



Literature citations
Molecular analysis of Sanfilippo syndrome type C in Spain: seven novel HGSNAT mutations and characterization of the mutant alleles.
Canals I.; Elalaoui S.C.; Pineda M.; Delgadillo V.; Szlago M.; Jaouad I.C.; Sefiani A.; Chabas A.; Coll M.J.; Grinberg D.; Vilageliu L.;
Clin. Genet. 80:367-374(2011)
Cited for: VARIANTS MPS3C VAL-82; PRO-141; VAL-452 AND PRO-473; VARIANT GLN-265; CHARACTERIZATION OF VARIANTS MPS3C VAL-82; PRO-141; CYS-372; VAL-452; PRO-473 AND PHE-546; CHARACTERIZATION OF VARIANT GLN-265;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.